ClinicalTrials.gg
Active, not recruitingNCT05471843Updated Sep 22, 2026Results posted

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

A Phase 1/2 interventional study of Sonrotoclax in Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL) and Relapsed Mantle Cell Lymphoma, sponsored by BeOne Medicines. Active, not recruiting at 65 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by BeOne Medicines · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines — 4 open to participants now, 6 under way, 2 of them phase 3. Lymphoma, Mantle-Cell · BeOne Medicines.

Enrollment
6th of 10
125 · median 136
Started
2022
with 1 other
Phase 1/2
6 of 10
3 open now
Registered
8th of 10
by date

Among the 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines, this one is the 6th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 1/2, and was the 8th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

4 of the 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines, or all of them as a file.
02

Study summary

The study consists of two parts. Part 1 determines the safety and tolerability of sonrotoclax monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of sonrotoclax monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of sonrotoclax monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.

03

Conditions studied

  • Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma (MCL)
  • Relapsed Mantle Cell Lymphoma

Keywords

  • Mantle Cell Lymphoma
  • Lymphoma
  • MCL
  • Refractory MCL
  • Refractory Mantle Cell Lymphoma
  • Relapsed Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed diagnosis of MCL
  2. Prior systemic treatments for MCL (at least one line of anti-cluster of differentiation 20 (anti-CD20) based immune or chemoimmunotherapy and at least one kind of covalent or non-covalent adequate Bruton Tyrosine Kinase (BTK) inhibitor).
  3. disease
  4. Presence of
  5. Availability of confirming diagnosis of MCL, or willing to undergo fresh tumor biopsy
  6. (ECOG) performance status of 0,1 or 2.
  7. Adequate organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Prior other than MCL within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer.
  3. Prior exposure to a BCL-2 inhibitor (eg, venetoclax/ABT-199).
  4. Prior stem cell transplant within the last 3 months; or prior autologous chimeric antigen receptor T-cell therapy within the last 3 months; or prior allogeneic stem cell transplant within the last 6 months or currently has an active graft-vs-host disease requiring the use of .
  5. cardiovascular disease.
  6. Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.
  7. Active fungal, bacterial or viral infection requiring systemic treatment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Part 1: Sonrotoclax 160 mg (Daily Ramp-up)

    Participants received sonrotoclax at the target dose of 160 mg orally once a day (QD) after an approximately 4-week ramp-up schedule starting at 1 mg with daily dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.

    Drug: Sonrotoclax

  • Experimental
    Part 1: Sonrotoclax 320 mg (Daily Ramp-up)

    Participants received sonrotoclax at the target dose of 320 mg orally once a day after an approximately 4-week ramp-up schedule starting at 1 mg with daily dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.

    Drug: Sonrotoclax

  • Experimental
    Part 2: Sonrotoclax 320 mg (Daily Ramp-up)

    Participants received sonrotoclax at the target dose of 320 mg orally once a day after an approximately 4-week ramp-up schedule starting at 1 mg with daily dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.

    Drug: Sonrotoclax

  • Experimental
    Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)

    Participants received sonrotoclax at the target dose of 320 mg orally once a day after an approximately 4-week ramp-up schedule starting at 1 mg with twice-weekly dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.

    Drug: Sonrotoclax

Interventions

  • Administered orally

    Also known as: BGB-11417

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)

    DLTs included the following events without a clear alternative cause other than study drug: Hematologic Toxicity: * Grade ≥ 3 febrile neutropenia; * Grade ≥ 3 thrombocytopenia lasting \> 7 days or resulting in clinically significant bleeding; * Any Grade ≥ 4 hematological toxicities, except for Grade 4 neutropenia lasting ≤ 7 days with or without treatment, Grade 4 lymphopenia, or Grade 4 leukopenia. Nonhematologic Toxicity: • Any Grade ≥ 3 nonhematologic toxicity with the following exceptions: * Laboratory tumor lysis syndrome (TLS) defined by the Howard criteria that resolves (≤ Grade 1 or baseline) in ≤ 3 days; * Individual TLS-related laboratory adverse events that resolve (≤ Grade 1or baseline) in ≤ 3 days with or without treatment; * Grade 3 gastrointestinal toxicity that resolves to ≤ Grade 2 following therapeutic intervention in ≤ 7 days; * Asymptomatic biochemical laboratory abnormalities that resolve (≤ Grade 1 or baseline) in ≤ 7 days with or without supportive care.

    Time frame: From first dose in the ramp-up period through the first 3 weeks of treatment at the target dose (approximately 7 weeks)

  2. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.

    Time frame: From first dose of study drug up to 30 days after last dose or the primary analysis data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months.

  3. Part 1: Number of Participants Experiencing Tumor Lysis Syndrome (TLS) Adverse Events

    Tumor lysis syndrome (TLS) occurs when large numbers of cancer cells die rapidly, releasing their contents (such as potassium, phosphorus, and nucleic acids) into the bloodstream faster than the kidneys can filter them out. This rapid breakdown causes a dangerous chain reaction of metabolic and electrolyte imbalances.

    Time frame: From first dose of study drug up to 30 days after last dose or the primary analysis data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months.

  4. Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)

    ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

Secondary outcomes

  1. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax After a Single Dose

    Time frame: Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose

  2. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax at Steady-State

    Time frame: Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose

  3. Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) After a Single Dose

    Time frame: Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose

  4. Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) at Steady State

    Time frame: Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose

  5. Part 1: Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax After a Single Dose

    Time frame: Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose

  6. Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State

    Time frame: Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose

  7. Part 1: Trough Plasma Concentration (Ctrough) at Steady State

    Time frame: Target Dose Week 4 Day 1 at predose

  8. Part 1: Overall Response Rate Assessed by the Independent Review Committee (IRC)

    ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  9. Part 1: Overall Response Rate Assessed by the Investigator

    ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per Lugano classification for non-Hodgkin lymphoma.

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  10. Part 1: Duration of Response (DOR) Assessed by the IRC

    DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause; whichever occurred first, per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. DOR was estimated using the Kaplan-Meier method.

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  11. Part 1: Duration of Response Assessed by the Investigator

    DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  12. Part 1: Progression Free Survival (PFS) Assessed by the IRC

    PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. PFS was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  13. Part 1: Progression-free Survival Assessed by the Investigator

    PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  14. Part 1: Time to Response (TTR) as Assessed by the IRC

    Time to response is defined as the time from start of treatment to first documentation of response (PR or better). IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in part 1 was 10.7 (0.1-31.6) months.

  15. Part 1: Time to Response Assessed by the Investigator

    TTR is defined as the time from start of treatment to first documentation of response (PR or better).

    Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  16. Part 1: Overall Survival (OS)

    Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.

  17. Part 2: Overall Response Rate (ORR) Assessed by the Investigator

    ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.

    Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  18. Part 2: Duration of Response Assessed by the IRC

    Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.

    Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  19. Part 2: Duration of Response Assessed by the Investigator

    Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.

    Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  20. Part 2: Progression-free Survival Assessed by the IRC

    PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.

    Time frame: From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  21. Part 2: Progression-free Survival Assessed by the Investigator

    PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.

    Time frame: From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  22. Part 2: Time to Response Assessed by the IRC

    Time to response is defined as the time from start of treatment to first documentation of response (PR or better).

    Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  23. Part 2: Time to Response Assessed by the Investigator

    Time to response is defined as the time from start of treatment to first documentation of response (PR or better).

    Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  24. Part 2: Overall Survival

    Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.

    Time frame: From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.

  25. Part 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Disease Related Symptoms-Physical (DRS-P) Sub-scale Score

    The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Disease Related Symptoms - Physical subscale score ranges from 0 to 36, where higher scores indicate better health-related quality of life (HRQoL).

    Time frame: Baseline and Weeks 4, 12, and 24

  26. Part 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Treatment Side-Effects (TSE) Sub-scale Score

    The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Treatment Side-Effects subscale score ranges from 0 to 12, where higher scores indicate better health-related quality of life (HRQoL).

    Time frame: Baseline and Weeks 4, 12, and 24

  27. Part 2: Change From Baseline in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale (VAS) Score

    The EQ-5D VAS measures participants' self-rated health status on a scale from 0 to 100, with 100 = 'the best health you can imagine' and 0 = 'the worst health you can imagine'. Higher scores on VAS indicate higher health status.

    Time frame: Baseline and Weeks 4, 12, and 24

  28. Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.

    Time frame: From first dose of study drug up to 30 days after last dose or the data cut-off date, whichever occurred earlier; maximum duration of treatment in Part 2 was 24.8 months.

07

Results

Posted Sep 22, 2026

Participant flow

This study is being conducted in 106 sites worldwide. Results are reported up to the primary analysis cut-off date of July 18, 2025.

Participant flow — Overall Study
MilestonePart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)
Started10124360
Completed0000
Not completed10124360
Withdrew: Death791721
Withdrew: Remain on study332334
Withdrew: Lost to follow-up0001
Withdrew: Physician decision0011
Withdrew: Withdrawal by subject0023

Outcome measures

PrimaryPart 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)

DLTs included the following events without a clear alternative cause other than study drug: Hematologic Toxicity: * Grade ≥ 3 febrile neutropenia; * Grade ≥ 3 thrombocytopenia lasting \> 7 days or resulting in clinically significant bleeding; * Any Grade ≥ 4 hematological toxicities, except for Grade 4 neutropenia lasting ≤ 7 days with or without treatment, Grade 4 lymphopenia, or Grade 4 leukopenia. Nonhematologic Toxicity: • Any Grade ≥ 3 nonhematologic toxicity with the following exceptions: * Laboratory tumor lysis syndrome (TLS) defined by the Howard criteria that resolves (≤ Grade 1 or baseline) in ≤ 3 days; * Individual TLS-related laboratory adverse events that resolve (≤ Grade 1or baseline) in ≤ 3 days with or without treatment; * Grade 3 gastrointestinal toxicity that resolves to ≤ Grade 2 following therapeutic intervention in ≤ 7 days; * Asymptomatic biochemical laboratory abnormalities that resolve (≤ Grade 1 or baseline) in ≤ 7 days with or without supportive care.

Time frame:
From first dose in the ramp-up period through the first 3 weeks of treatment at the target dose (approximately 7 weeks)
Reported as:
Count of participants · Participants
Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
ParticipantsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)00
PrimaryPart 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.

Time frame:
From first dose of study drug up to 30 days after last dose or the primary analysis data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months.
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation
ParticipantsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
TEAEs1012
SAEs65
TEAE Leading to Treatment Discontinuation21
PrimaryPart 1: Number of Participants Experiencing Tumor Lysis Syndrome (TLS) Adverse Events

Tumor lysis syndrome (TLS) occurs when large numbers of cancer cells die rapidly, releasing their contents (such as potassium, phosphorus, and nucleic acids) into the bloodstream faster than the kidneys can filter them out. This rapid breakdown causes a dangerous chain reaction of metabolic and electrolyte imbalances.

Time frame:
From first dose of study drug up to 30 days after last dose or the primary analysis data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months.
Reported as:
Count of participants · Participants
Part 1: Number of Participants Experiencing Tumor Lysis Syndrome (TLS) Adverse Events
ParticipantsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Number of Participants Experiencing Tumor Lysis Syndrome (TLS) Adverse Events01
PrimaryPart 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)

ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Number · percentage of participants
Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)
percentage of participantsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)44.2 (29.1 to 60.1)58.3 (44.9 to 70.9)52.4 (42.4 to 62.4)
Statistical analysis
  • Part 2: Sonrotoclax 320 mg Total · Binomial exact test · p = <0.0001 (1-sided P value)
SecondaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax After a Single Dose
Time frame:
Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax After a Single Dose
h*ng/mLPart 1: Sonrotoclax Daily Ramp-up
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax After a Single Dose8.64 ± 67
SecondaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax at Steady-State
Time frame:
Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax at Steady-State
h*ng/mLPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax at Steady-State1208.05 ± 272810.79 ± 72
SecondaryPart 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) After a Single Dose
Time frame:
Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Reported as:
Median · hours
Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) After a Single Dose
hoursPart 1: Sonrotoclax Daily Ramp-up
Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) After a Single Dose4.00 (2.0 to 7.5)
SecondaryPart 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) at Steady State
Time frame:
Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Reported as:
Median · hours
Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) at Steady State
hoursPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) at Steady State4.12 (3.9 to 6.0)4.09 (1.9 to 8.0)
SecondaryPart 1: Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax After a Single Dose
Time frame:
Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax After a Single Dose
ng/mLPart 1: Sonrotoclax Daily Ramp-up
Part 1: Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax After a Single Dose1.84 ± 51
SecondaryPart 1: Maximum Observed Plasma Concentration (Cmax) at Steady State
Time frame:
Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State
ng/mLPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State223.84 ± 34559.76 ± 103
SecondaryPart 1: Trough Plasma Concentration (Ctrough) at Steady State
Time frame:
Target Dose Week 4 Day 1 at predose
Reported as:
Geometric mean · ng/mL
Part 1: Trough Plasma Concentration (Ctrough) at Steady State
ng/mLPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Trough Plasma Concentration (Ctrough) at Steady State17.31 ± 13450.49 ± 57
SecondaryPart 1: Overall Response Rate Assessed by the Independent Review Committee (IRC)

ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Number · percentage of participants
Part 1: Overall Response Rate Assessed by the Independent Review Committee (IRC)
percentage of participantsPart 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Overall Response Rate Assessed by the Independent Review Committee (IRC)50.0 (21.1 to 78.9)
SecondaryPart 1: Overall Response Rate Assessed by the Investigator

ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per Lugano classification for non-Hodgkin lymphoma.

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Number · percentage of participants
Part 1: Overall Response Rate Assessed by the Investigator
percentage of participantsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Overall Response Rate Assessed by the Investigator40.0 (12.2 to 73.8)41.7 (15.2 to 72.3)
SecondaryPart 1: Duration of Response (DOR) Assessed by the IRC

DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause; whichever occurred first, per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. DOR was estimated using the Kaplan-Meier method.

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Duration of Response (DOR) Assessed by the IRC
monthsPart 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Duration of Response (DOR) Assessed by the IRC6.0 (0.9 to NA)
SecondaryPart 1: Duration of Response Assessed by the Investigator

DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Duration of Response Assessed by the Investigator
monthsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Duration of Response Assessed by the InvestigatorNA (7.3 to NA)2.8 (2.2 to NA)
SecondaryPart 1: Progression Free Survival (PFS) Assessed by the IRC

PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. PFS was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Progression Free Survival (PFS) Assessed by the IRC
monthsPart 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Progression Free Survival (PFS) Assessed by the IRC3.8 (1.6 to 22.9)
SecondaryPart 1: Progression-free Survival Assessed by the Investigator

PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Progression-free Survival Assessed by the Investigator
monthsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Progression-free Survival Assessed by the Investigator5.4 (0.5 to NA)3.5 (1.6 to 6.5)
SecondaryPart 1: Time to Response (TTR) as Assessed by the IRC

Time to response is defined as the time from start of treatment to first documentation of response (PR or better). IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Time to Response (TTR) as Assessed by the IRC
monthsPart 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Time to Response (TTR) as Assessed by the IRC1.81 (1.7 to 2.1)
SecondaryPart 1: Time to Response Assessed by the Investigator

TTR is defined as the time from start of treatment to first documentation of response (PR or better).

Time frame:
Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Time to Response Assessed by the Investigator
monthsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Time to Response Assessed by the Investigator1.89 (1.4 to 3.6)3.55 (1.7 to 6.5)
SecondaryPart 1: Overall Survival (OS)

Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Reported as:
Median · months
Part 1: Overall Survival (OS)
monthsPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)
Part 1: Overall Survival (OS)11.4 (0.7 to NA)9.5 (0.7 to NA)
SecondaryPart 2: Overall Response Rate (ORR) Assessed by the Investigator

ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.

Time frame:
Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Number · percentage of participants
Part 2: Overall Response Rate (ORR) Assessed by the Investigator
percentage of participantsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Overall Response Rate (ORR) Assessed by the Investigator41.9 (27.0 to 57.9)51.7 (38.4 to 64.8)47.6 (37.6 to 57.6)
SecondaryPart 2: Duration of Response Assessed by the IRC

Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.

Time frame:
Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Duration of Response Assessed by the IRC
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Duration of Response Assessed by the IRC15.8 (4.7 to NA)12.4 (7.2 to NA)15.8 (7.4 to NA)
SecondaryPart 2: Duration of Response Assessed by the Investigator

Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.

Time frame:
Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Duration of Response Assessed by the Investigator
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Duration of Response Assessed by the Investigator17.2 (7.4 to NA)13.1 (6.7 to NA)15.8 (8.4 to NA)
SecondaryPart 2: Progression-free Survival Assessed by the IRC

PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.

Time frame:
From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Progression-free Survival Assessed by the IRC
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Progression-free Survival Assessed by the IRC6.3 (1.7 to 9.1)9.1 (4.0 to NA)6.5 (4.0 to 10.4)
SecondaryPart 2: Progression-free Survival Assessed by the Investigator

PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.

Time frame:
From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Progression-free Survival Assessed by the Investigator
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Progression-free Survival Assessed by the Investigator3.7 (1.7 to 9.1)8.6 (4.3 to 12.0)6.4 (3.7 to 9.1)
SecondaryPart 2: Time to Response Assessed by the IRC

Time to response is defined as the time from start of treatment to first documentation of response (PR or better).

Time frame:
Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Time to Response Assessed by the IRC
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Time to Response Assessed by the IRC1.87 (1.7 to 4.6)1.94 (1.6 to 6.2)1.91 (1.6 to 6.2)
SecondaryPart 2: Time to Response Assessed by the Investigator

Time to response is defined as the time from start of treatment to first documentation of response (PR or better).

Time frame:
Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Time to Response Assessed by the Investigator
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Time to Response Assessed by the Investigator1.89 (1.7 to 3.9)1.94 (1.6 to 4.0)1.91 (1.6 to 4.0)
SecondaryPart 2: Overall Survival

Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.

Time frame:
From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Reported as:
Median · months
Part 2: Overall Survival
monthsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Part 2: Overall SurvivalNA (7.3 to NA)NA (14.8 to NA)NA (14.8 to NA)
SecondaryPart 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Disease Related Symptoms-Physical (DRS-P) Sub-scale Score

The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Disease Related Symptoms - Physical subscale score ranges from 0 to 36, where higher scores indicate better health-related quality of life (HRQoL).

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Least squares mean · score on a scale
Part 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Disease Related Symptoms-Physical (DRS-P) Sub-scale Score
score on a scalePart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Week 42.1 (0.3 to 3.8)0.9 (-0.3 to 2.1)1.4 (0.4 to 2.4)
Week 121.4 (-0.4 to 3.2)2.3 (1.0 to 3.5)1.9 (0.9 to 3.0)
Week 241.2 (-0.7 to 3.1)1.2 (-0.2 to 2.5)1.2 (0.1 to 2.3)
SecondaryPart 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Treatment Side-Effects (TSE) Sub-scale Score

The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Treatment Side-Effects subscale score ranges from 0 to 12, where higher scores indicate better health-related quality of life (HRQoL).

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Least squares mean · score on a scale
Part 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Treatment Side-Effects (TSE) Sub-scale Score
score on a scalePart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Week 40.5 (-0.2 to 1.2)0.4 (-0.2 to 0.9)0.4 (-0.0 to 0.9)
Week 120.6 (-0.2 to 1.4)1.0 (0.4 to 1.6)0.8 (0.4 to 1.3)
Week 240.2 (-0.6 to 1.0)0.9 (0.3 to 1.5)0.6 (0.1 to 1.1)
SecondaryPart 2: Change From Baseline in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale (VAS) Score

The EQ-5D VAS measures participants' self-rated health status on a scale from 0 to 100, with 100 = 'the best health you can imagine' and 0 = 'the worst health you can imagine'. Higher scores on VAS indicate higher health status.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Part 2: Change From Baseline in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale (VAS) Score
score on a scalePart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
Week 48.5 ± 12.191.0 ± 13.363.9 ± 13.33
Week 127.7 ± 11.054.4 ± 15.145.7 ± 13.67
Week 2410.0 ± 14.684.3 ± 20.086.5 ± 18.22
SecondaryPart 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.

Time frame:
From first dose of study drug up to 30 days after last dose or the data cut-off date, whichever occurred earlier; maximum duration of treatment in Part 2 was 24.8 months.
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation
ParticipantsPart 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Part 2: Sonrotoclax 320 mg Total
TEAEs435699
SAEs142438
TEAE Leading to Treatment Discontinuation51015

Adverse events

Collected over From first dose of study drug up to 30 days after last dose or the data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months in Part 1 and 24.8 months in Part 2.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Sonrotoclax 160 mg (Daily Ramp-up)7/10 (70%)6/10 (60%)10/10 (100%)
Part 1: Sonrotoclax 320 mg (Daily Ramp-up)9/12 (75%)5/12 (41.7%)12/12 (100%)
Part 2: Sonrotoclax 320 mg (Daily Ramp-up)17/43 (39.5%)14/43 (32.6%)42/43 (97.7%)
Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)21/60 (35%)24/60 (40%)51/60 (85%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)
AnaemiaBlood and lymphatic system disorders1/100/120/431/60
DeathGeneral disorders and administration site conditions1/100/120/431/60
COVID-19 pneumoniaInfections and infestations1/100/120/431/60
PneumoniaInfections and infestations1/101/123/436/60
Respiratory tract infectionInfections and infestations1/100/120/430/60
Platelet count decreasedInvestigations1/101/121/431/60
DyspnoeaRespiratory, thoracic and mediastinal disorders1/100/120/430/60
Cardiac failure congestiveCardiac disorders0/101/120/431/60
DiarrhoeaGastrointestinal disorders0/101/120/430/60
AppendicitisInfections and infestations0/101/120/430/60
Most frequent other events
Showing 10 of 126
Most frequent other events
EventPart 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)
HypokalaemiaMetabolism and nutrition disorders8/105/1211/434/60
White blood cell count decreasedInvestigations7/104/1211/4310/60
Neutrophil count decreasedInvestigations6/105/1214/439/60
AnaemiaBlood and lymphatic system disorders5/104/1210/4312/60
Platelet count decreasedInvestigations5/101/125/435/60
Aspartate aminotransferase increasedInvestigations1/104/123/437/60
HypoalbuminaemiaMetabolism and nutrition disorders1/104/121/432/60
HypocalcaemiaMetabolism and nutrition disorders1/104/125/431/60
ConstipationGastrointestinal disorders3/101/123/438/60
Lymphocyte count decreasedInvestigations3/101/124/431/60

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Total
<=18 years00000
Between 18 and 65 years53191946
>=65 years59244179
Age, Continuous
Age, Continuous(years)Part 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Total
Median64.0 (43 to 74)70.5 (52 to 76)66.0 (43 to 85)69.0 (39 to 85)68.0 (39 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Total
Female31101731
Male711334394
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Total
Hispanic or Latino0071825
Not Hispanic or Latino1012344197
Unknown or Not Reported00213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Total
Asian1011211355
White01184261
Black or African American00123
Other00224
Not Reported00112
Eastern Cooperative Oncology Group Performance (ECOG) Performance Status
Eastern Cooperative Oncology Group Performance (ECOG) Performance Status(Participants)Part 1: Sonrotoclax 160 mg (Daily Ramp-up)Part 1: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Daily Ramp-up)Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)Total
0 (Fully active)24161436
1 (Restricted but ambulatory)78273981
2 (Ambulatory but unable to work)10078
08

Study locations

65 sites
09

References and documents

Publications

  • Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017 Nov 2;10(1):171. doi: 10.1186/s13045-017-0537-5. PubMed 29096668 ↗
  • Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 Aug;182(3):404-411. doi: 10.1111/bjh.15411. Epub 2018 May 22. PubMed 29785709 ↗
  • Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13. PubMed 26764355 ↗
  • Eyre TA, Song Y, Hermine O, Shuang Y, Jurczak W, Farias JS, Mahuad C, Ozcan M, Jachimowicz RD, Chen T, Ivanova E, Li X, Man G, Bourquelot P, Vezan R, Wang M. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. J Clin Oncol. 2026 Jul 1:JCO2600550. doi: 10.1200/JCO-26-00550. Online ahead of print. PubMed 42385124 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2025, 34 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

Of 77 phase 1/2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 114. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Jul 25, 2022
StartActual
Sep 5, 2022
Primary completionActual
Jul 18, 2025
CompletionEst.
Jan 31, 2027
Results first posted
Sep 22, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05471843
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jul 25, 2022
Start date
Sep 5, 2022
Primary completion
Jul 18, 2025
Completion
Jan 31, 2027 (estimated)
Results posted
Sep 22, 2026
Last update
Sep 22, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion